

# hentoTouch

THE FUTURE OF ALCOHOL  
USE DISORDER TREATMENT

## hentoTouch



**BUSINESS  
FINLAND**

WE ARE CREATING A  
DISCREET, NON-INVASIVE,  
NEUROMODULATING  
MEDICAL DEVICE FOR  
ALCOHOL RELAPSE  
PREVENTION

### COMPETITIVE ADVANTAGE

- Low-threshold access to treatment, home delivery and immediate availability
- Safe, non-invasive and non-pharmacological treatment
- Discreet, the device can be used under clothes anywhere and anytime

### IPR STATUS

- Patent pending




- TARGETED NEURAL ACTIVATION
- TOLERANCE TO STRESS- AND CUE-INDUCED ALCOHOL CRAVING
- RELAPSE PREVENTION

### PROBLEM

Alcohol use disorder (AUD) is one of the largest health threats in the world, with an economic burden of more than 1 trillion €. AUD is also one of the most undertreated mental disorders: 78% of patients never receive any treatment, and 85% of those who stop drinking with current treatments return to drinking. The problems with current treatments include high stigma and complicated access to treatment with long waiting times. E.g., no self-care solutions for AUD available over the counter.

### THE ASK

- We are looking for new networks in medical technologies, especially in occupational healthcare business sector, pharmaceutical industry and industrial partners to expedite our go-to-market.
- We seek seed stage investors, matching investment up to 600k€ Q3 2023



[www.hentotouch.com](http://www.hentotouch.com)

### TEAM MEMBERS

**Jukka Planman**, Commercial Champion  
[jukka.planman@aalto.fi](mailto:jukka.planman@aalto.fi), +358 50 309 9887  
**Juliana Harkki**, Medical Lead  
**Pauli Tuovinen**, Technology Lead  
**Ilkka Hyytiäinen**, Aalto Innovation Services

### RESPONSIBLE LEADER

**Heikki Nieminen**,  
Professor, Principal Investigator  
Aalto University  
[heikki.j.nieminen@aalto.fi](mailto:heikki.j.nieminen@aalto.fi)

**SPARK**  
—FINLAND